News

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...
The patient’s grade 4 bullous pemphigoid emerges despite cabozantinib dose reduction, requiring high-dose corticosteroids and rituximab to achieve resolution.
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...
If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...
Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst ...
Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a ...